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Objectives: To evaluate the role of multiparametric magnetic resonance imaging in 
improving the predictive accuracy of the Prostate Cancer Research International: Active 
Surveillance and Epstein criteria for active surveillance in prostate cancer. 
Methods: A retrospective study was carried out with 126 prostate cancer patients 
treated with robot-assisted radical prostatectomy, but eligible for active surveillance 
according to the Prostate Cancer Research International: Active Surveillance criteria; 63 
patients were also eligible according to the Epstein criteria. All patients underwent 
preoperative multiparametric magnetic resonance imaging, after at least 6 weeks from 
biopsy. The images from the multiparametric magnetic resonance imaging were 
assessed, and diagrams showing prostate sextants were used to designate regions of 
abnormalities within the prostate. Findings in the prostate were assigned to one of five 
categories according the Prostate Imaging-Reporting and Data System guidelines (v1.0), 
and considered positive for prostate cancer if the final Prostate Imaging-Reporting and 
Data System guidelines were >3 and negative if ≤3. Multivariate logistic regression 
analysis was carried out to evaluate the gain in accuracy of the Prostate Cancer 
Research International: Active Surveillance and Epstein criteria when added to 
multiparametric magnetic resonance imaging. Decision curve analysis was carried out to 
identify the net benefit of each model. 
Results: The inclusion of multiparametric magnetic resonance imaging to the Epstein 
criteria and the Prostate Cancer Research International: Active Surveillance multivariate 
model significantly increased their accuracy in predicting pathologically-confirmed 
insignificant prostate cancer by 7% and 5%, respectively. At the decision curve analysis 
evaluation, the model including the Prostate Cancer Research International: Active 
Surveillance criteria and multiparametric magnetic resonance imaging improved the 
clinical risk prediction over the other models. 
Conclusions: The present findings suggest that multiparametric magnetic resonance 
imaging is able to increase the predictive accuracy of Prostate Cancer Research 
International: Active Surveillance and Epstein criteria to identify prostate cancer patients 
eligible for active surveillance. 
Key words: active surveillance, multiparametric magnetic resonance imaging, 
prognostic accuracy, prostate cancer, radical prostatectomy. 
 
Introduction 
Several studies considering RP specimens as the reference standard showed that mpMRI has 
an excellent sensitivity for larger and more aggressive (GS ≥7) PCa.1–3 Therefore, mpMRI 
allows better identification of patients with clinically significant disease and, consequently, 
has the potential to rule out patients with insignificant disease from active treatment when 
mpMRI is negative.4 
In this context, several studies showed the primary importance of DWI during mpMRI. 
The ADC resulting from DWI provides information on tumor aggressiveness. Recently, it has 
been documented that ADC values are inversely correlated with GS in PCa, and might be 
helpful in differentiation of low-, intermediate- and high-risk cancer.5 Furthermore, ADC 
candidates for AS, as well as for predicting PCa progression 
during the monitoring of these patients.6 
The actual AS criteria are not perfect, misclassifying some 
patients that are selected with apparent low-risk disease and 
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then harboring unfavorable disease.7 In contrast, we must not 
forget that current AS criteria might be too strict. In this context, 
GS 3 + 4 patients, with a very small volume of a secondary 
Gleason 4 and a PSA <10 ng/mL, have been shown 
to have a disease comparable with GS 3 + 3 patients.8,9 Van 
der Bergh et al. recently published a systematic review of 30 
studies regarding all new clinical tools (mpMRI, serum 
biomarkers [_2proPSA and the Prostate Health Index] and 
urinary markers [PCa antigen 3 gene]) for a better selection 
and monitoring in patients submitted to AS.10 The authors 
concluded that the use of high-quality mpMRI was promising 
because of the very high negative predictive value with 
respect to significant PCa, and a favorable mpMRI might 
obviate the need for repeat biopsy during AS. 
Keeping this in mind, we tested the hypothesis that 
mpMRI could improve the two most frequently used criteria 
for AS, the PRIAS and Epstein criteria, in a cohort of 
patients that underwent RP, but were eligible for AS, using 
RP specimens as the reference standard. 
Methods 
Study population 
A study was carried out among 126 patients with low-risk PCa 
who underwent robot-assisted RP at a surgical high-volume 
center (San Luigi Hospital, University of Turin, Orbassano, 
Turin, Italy) from January 2012 to February 2015. 
Such patients, according to common clinical practice at this 
center, were evaluated with mpMRI before surgery, used for 
local staging and carried out after 6–8 weeks from 12-core 
systematic transrectal biopsy in order to minimize postbiopsy 
artifacts. mpMRI was carried out at two centers with expertise 
in mpMRI, San Luigi Hospital, Orbassano (Turin), 
University of Turin and Institute for Cancer Research and 
Treatment of Candiolo (Turin). All patients were eligible for 
AS according to the PRIAS criteria (clinical stage T1c or T2 
disease, PSA level of ≤10 ng/mL, GS ≤6, PSA-D of 
<0.20 ng/mL/cc and one or two positive biopsy cores). 
Among these patients, 63 (50%) were also eligible for AS 
according to the Epstein criteria (clinical stage T1c, PSA 
level ≤10 ng/mL, GS ≤6, PSA-D ≤0.15 ng/mL, one or two 
positive biopsy cores and percentage of core involvement 
≤50%). In particular, the patients had been proposed for AS, 
only based on clinical and biopsy data, but they finally had 
refused, opting for surgery. 
All clinical, mpMRI and final histopathological features 
were retrospectively analyzed. 
mpMRI 
Patients preoperatively underwent a mpMRI with a 1.5-Tesla 
scanner (Signa Excite HD; GE Healthcare, Milwaukee, WI, 
USA) using a four-channel phase array coil combined with 
an endorectal coil (Medrad, Warrendale, PA, USA) or with a 
1.5 Tesla scanner (Achieva HD; Philips Healthcare, Best, The 
Netherlands) using a five-channel phase array coil combined 
with an endorectal coil (Medrad). Studies were carried out 
with: (i) T2-weighted images in the axial, coronal and sagittal 
planes to evaluate the prostate and seminal vesicle anatomy; 
(ii) T1 fast spin echo axial images to identify areas of 
intraprostatic hemorrhage, and to evaluate the pelvic lymph 
nodes and bones; and (iii) DWI and DCE images in order to 
obtain biological and functional information. DWI was carried 
out using axial echo planar imaging sequences at different 
b-values: 0–100–1000–2000 s/mm2. The sequences 
parameters satisfied the recommendations from a European 
consensus meeting on MRI imaging for the detection, localization 
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and characterization of PCa.11 
All images were sent to two workstations and post-processed 
(Functool v. 9.4.05a; GE Healthcare; and Intellispace 
Portal v. 6.0.3.12200; Philips Healthcare). Two experienced 
uroradiologists analyzed the mpMRI findings identifying all 
the suspicious ROIs. The uroradiologists were blinded to the 
pathologist biopsy reports. Diagnostic features for malignancy 
have been reported in Appendix S1. 
Each ROI was assessed, and diagrams showing the prostate 
sextants were used to designate regions of abnormalities 
within the prostate. In addition, each ROI was scored on a 
scale ranging from 1 to 5, with higher scores indicative of 
higher suspicion of cancer, according to the PI-RADS (v1.0) 
guidelines, developed by the European Society of Urogenital 
Radiology in order to standardize the evaluation and reporting 
of prostate mpMRI.12 
In particular, a 0–5 score was assigned to each of the three 
MRI sequences for single ROI (T2-weighted, DWI and 
DCE), and a single final PI-RADS score was obtained. Overall, 
we dichotomized the variable, and the mpMRI finding 
was considered positive if the final PI-RADS was >3, and 
negative if ≤3. In case of multiple ROIs, we considered only 
the index lesion, considered as the lesion with the highest PIRADS 
score. 
Pathology evaluation 
RP specimens were evaluated using serially 3-mm sectioned 
whole-mount specimens according to the Stanford protocol,13 
and primary and secondary GS were assigned by an experienced 
uropathologist, blinded to the mpMRI results, according 
to the 2005 consensus conference of the International 
Society of Urological Pathology definitions.14 
For study purposes, all tumor foci were identified. Specifically, 
we evaluated the index tumor, defined as the tumor 
with the highest GS. When multiple tumors had the same 
grade, the largest tumor focus was considered as the index 
tumor (we considered approximately a lesion of 1 cm corresponding 
to a spherical volume of 0.5 mL). In addition, we 
evaluated the cumulative tumor volume using computerized 
planimetry accounting for all tumor foci.15 
Study end-points 
Based on the high NPV in ruling out a significant PCa, the 
primary end-point of the study was to determine the 
using the European Randomized Screening for Prostate Cancer 
definition (organ-confined Gleason 3 + 3 tumors, with no 
Gleason grade 4 or 5, index tumor volume ≤1.3 cm3 and a 
total tumor volume of ≤2.5 cm3).16 In addition, we evaluated 
the gain in predictive accuracy obtained with the addition of 
mpMRI to the PRIAS criteria or Epstein criteria. In accordance 
with other authors, we used this criteria because we 
consider the Epstein definition of insignificant PCa too 
restrictive regarding the PCa volume threshold of 0.5 cm3 for 
the index tumor.17 Indeed, despite a 5% increase in the risk 
of underestimation of significant PCa, a larger proportion of 
men would have the chance to follow an AS program. 
Statistical analysis 
The qualitative data were tested using the v2-test or Fisher’s 
exact test as appropriate, and the continuous variables were 
tested by Mann–Whitney U-test or Student’s t-test according 
to their distribution (according to Kolmogorov–Smirnov test) 
and presented as median (IQR) or mean (_SD), respectively. 
Univariate and multivariate logistic regression analyses were 
carried out to identify variables potentially predictive of 
PCIPCa. 
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Predictive accuracy of the models was assessed in terms of 
the AUC value. A total of 1000 bootstrap resamples were 
used for all accuracy estimates and to reduce overfit bias. 
AUC were compared by the Mantel–Haenszel test. 
We carried out DCA to evaluate the potential clinical usefulness 
of identifying PCIPCa based on the models including 
mpMRI.18 
We estimated NB for prediction models by summing the 
benefits (true positive PCIPCa) and subtracting the harms 
(false positive PCIPCa). The threshold probability of each 
model was estimated. We used a threshold probability 
between 0% and 80%. The interpretation of DCA is straightforward; 
a model with the highest NB at a particular threshold 
should be chosen over alternative models. For all 
statistical comparisons, significance was considered as 
P < 0.05. Standard statistical software was used (SPSS v.18.0; 
IBM Corp, Armonk, NY, USA; and R version 2.15.2; R 
Foundation for Statistical Computing, Vienna, Austria). 
Results 
At the final histopathological examination, we observed a 
reclassification in 57 patients (45.2%). A total of 126 dominant 
lesions were identified, 87 with volume ≤1.3 mL and 39 
with volume >1.3 mL. A total of 89 patients had GS ≤6, 
whereas 37 GS ≥7. We also identified five extracapsular 
extensions (Table 1). 
Overall, mpMRI showed 94 ROIs in 69 positive mpMRI 
patients. The sensitivity of mpMRI (PI-RADS >3) was 
73.7%, the specificity (PI-RADS ≤3) was 60.8%. The PPV 
for significant PCa was 60.8%, the NPV for ruling out significant 
PCa and identifying insignificant PCa was 73.7% 
(Table 1). 
At multivariate analysis and after 1000 bootstrapping 
resampling, the inclusion of mpMRI to the Epstein 
multivariate model, including total PSA, density PSA, number 
of positive cores (1 vs 2) and percentage of core involvement, 
adjusted for age, significantly increased its accuracy in 
predicting PCIPCa of 7%. Similarly, the inclusion of mpMRI 
to the PRIAS multivariate model, including total PSA, density 
PSA, clinical stage (T1 vs T2) and number of positive 
cores (2 vs 1), adjusted for age, significantly increased its 
accuracy in predicting PCIPCa of 5% (Table 2; Fig. 1). 
At the DCA evaluation, for patients with a threshold >60% 
of probability of pathologically favorable PCa, the model 
including PRIAS and mpMRI improved the clinical risk prediction 
over the other models (Fig. 2). 
Discussion 
AS is a valid tool to mitigate the risk of overtreatment of 
low-risk PCa. Recently, Klots et al. confirmed the feasibility 
of AS in a large cohort study with a long-term follow up.19 
However, during the first 2 years of AS, approximately 20– 
30% of patients shift toward definitive treatment because of a 
reclassification into higher-grade tumors.20 For this reason, 
there is a need to better identify the tumors bound to progress 
over time. 
In a cohort of patients eligible for AS according to the 
PRIAS criteria who underwent RP, using RP specimens as 
the reference standard, our group showed that mpMRI performed 
better than serum (Prostate Health Index) and urinary 
(PCa antigen 3) markers in predicting the pathological outcomes, 
better discriminating between insignificant and significant 
PCa.7 Consequently, in the present study, we evaluated 
the possibility of adding mpMRI to the PRIAS and Epstein 
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criteria to improve its predictive accuracy and preoperative 
definition of insignificant PCa. In the present study cohort, 
we observed a PPV for high-risk PCa of 60.8%, and a NPV 
for ruling out significant PCa of 73.7%. At multivariate analysis, 
we showed that mpMRI is able to increase the predictive 
accuracy of Epstein and PRIAS multivariate models of 
7% and 5%, respectively (P < 0.01). In addition, we carried 
out DCA for the predictive models previously developed. 
Only the model with PRIAS criteria + mpMRI resulted in a 
greater NB than other models at a threshold of probabilities 
>60%. Therefore, the present results would recommend the 
use of mpMRI in addition to actual AS criteria and, according 
to the results of DCA, the best model to select low-risk 
PCa patients eligible for AS is represented by PRIAS criteria 
and mpMRI. In this context, according to a recent study, 
PRIAS criteria showed the highest ability in identifying 
patients with insignificant PCa compared with all the other 
available criteria.21 
However, in contrast, we must not forget that PPV of 
mpMRI for predict significant PCa was relatively low at 
60.8%. Consequently, approximately 40% of patients with 
positive mpMRI and who fulfilled the PRIAS criteria showed 
insignificant PCa. Therefore, we can speculate that if all 
patients fulfilled the PRIAS criteria, but with positive mpMRI 
were treated with immediate radical treatments, at least 40% 
of patients would be overtreated. For this reason, we must 
always carry out a pathological evaluation by prostate biopsy 
in order to identify appropriate candidates for AS or during 
AS follow up. 
In a recent systematic review, although characterized by 
remarkable heterogeneity, Schoots et al. analyzing 10 studies 
with patients eligible for AS, but who underwent RP with preoperatively 
MRI, showed that the likelihood of a preoperative 
positive MRI was 73%, and upgrading occurred in 43% of 
patients with positive MRI (vs 27% of patients with negative 
MRI), whereas no difference occurred in terms of upstaging 
between the two groups.22 In addition, they analyzed data from 
seven studies with patients eligible for AS undergoing a confirmatory 
mpMRI and a subsequent systematic random biopsy or 
MRI-guided targeted biopsy. The authors showed that MRI 
was positive in two-thirds of men: in this group, biopsy reclassification 
occurred in 39% (vs 17% in patients with negative 
MRI). Focusing on the group with positive MRI and MRIguided 
targeted biopsy only, biopsy reclassification occurred in 
47% of cases. Finally, analyzing two studies with patients on 
AS follow up that underwent repeated MRI, the authors 
reported a strong correlation between positive MRI and 
upgrading during follow up and the possibility of avoiding 
biopsy in men with stable PSA and negative MRI. 
In another recent systematic review and meta-analysis of 
studies with patients eligible for AS submitted to MRI, Guo 
et al. showed that mpMRI had a moderate diagnostic accuracy 
in disease reclassification among AS candidates.23 In 
particular, they showed a high NPV and specificity for biopsy 
reclassification, suggesting that negative prostate mpMRI 
might support remaining under an AS protocol. In contrast, 
the PPV and sensitivity were relatively low, but, in the case 
of lesions of >10 mm in volume, the presence of a suspicious 
mpMRI might suggest an increased risk of disease progression. 
Most recently, Diaz et al. confirmed that mpMRI associated 
with MRI/transrectal ultrasound fusion biopsy 
substantially increased the number of pathological progressions 
detected that would not have been detected by standard 
biopsy alone.24 In addition, stable findings on mpMRI were 
strongly associated with GS stability in patients under AS. 
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This could potentially reduce the number of unnecessary 
biopsies during AS follow up. 
We agree with Giannarini et al. that mpMRI has yet many 
problems to solve before being accepted for routine clinical 
practice on a large scale.25 However, the present study helps 
to validate the clinical utility of mpMRI in a setting of 
patients under AS using RP specimens as the reference standard, 
that represents the best method for a clinical validation. 
Unfortunately, we did not carry out a matching between each 
mpMRI ROI with the corresponding locations on wholemount 
pathology, because we only considered the MRI findings 
as dichotomized MRI variable (patients with MRI positive 
or negative) and the index tumor with cumulative tumor 
volume on histological findings. Our future challenge will be 
to revalue each ROI on MRI findings and each tumor lesion 
on RP specimens in order to evaluate the grade concordance 
in terms of size and grade. Another problem related to MRI 
is the detection of TZ tumors. In the present study, we did 
not consider as suspicious all the lesions with PI-RADS 3, 
especially those located in the TZ that are, in most cases, secondary 
to inflammation or adenomatous nodules. Only 
poorly-defined nodules that distorted the normal architecture 
and had concordant anomalies on DWI and DCE were considered 
suspicious for malignancy, and were classified as PIRADS 
4 or 5. Several studies have showed that mpMRI did 
not improve the accuracy of detection and localization of TZ 
cancers compared with T2-weighted sequences alone for its 
low specificity.26 
The present study was limited by the relatively small number 
of cases examined. Further studies with a larger population 
should be carried out to confirm our findings. The 
inclusion of two expert uroradiologists who interpreted the 
mpMRI could generate an interobserver variability in interpreting 
imaging findings. However, the radiologists had the 
same level of expertise (more than 2 years of experience and 
more than 200 prostate mpMRI examined). PI-RADS v1.0 
and not the more recent v2.0 was used, potentially affecting 
the diagnostic accuracy, especially for the anterior ROI. However, 
a recent meta-analysis on the use of PI-RADS v1.0 for 
PCa detection with mpMRI showed a good diagnostic accuracy 
with a sensitivity of 0.78 and a specificity of 0.79.27 
Finally, the present study did not include any discussion 
regarding costs. However, we believe that the higher cost of 
mpMRI could be mitigated over time because of the economic 
effect generated by a better risk assessment with a 
more accurate identification of patients eligible to AS, reducing 
the overtreatment of indolent tumors, and reducing unnecessary 
biopsies during follow up. 
In conclusion, mpMRI might play an important role in the 
selection of low-risk PCa patients eligible for AS. In particular, 
using RP specimens as the standard reference, we showed 
that mpMRI is able to significantly increase the predictive 
accuracy of the PRIAS and Epstein criteria. However, robust 
data from prospective studies are required before adoption of 
mpMRI on a large scale for this purpose. 
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